TOP STORIES

• REGULATORY Novartis Fails to Report Nearly 5,500 Side Effect Cases, Biz Improvement Order Likely This Month
  November 10, 2015

• REGULATORY Chuikyo Wants to Stick to 14-Day Prescription Limit
  November 9, 2015

• BUSINESS Half-Year Revenues of 4 Japanese Majors Beat Projections on Buoyant Global Products
  November 6, 2015

• REGULATORY Chuikyo Doctor Reps Positive, but Payers Wary about Industry’s Ideas on “Essential Drugs”
  November 5, 2015

• REGULATORY Pricing Rule for Essential Drugs Top Priority in FY2016 Reform: Ex-MHLW Economic Affairs Head
  November 4, 2015

• REGULATORY MHLW Weighs Another Business Improvement Order to Novartis
  November 4, 2015

• BUSINESS Sakigake Designation System Very Useful: Astellas President
  November 2, 2015

• REGULATORY MOF Proposes Full Implementation of Cost-Effective Assessments as Precondition for Full-Scale Introduction of Premium for New Drug Development
  November 2, 2015

• TRENDS Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
  October 30, 2015

• REGULATORY Chuikyo Sees Big Chorus for Further Reforms in Generic Pricing
  October 29, 2015

• REGULATORY MHLW Eager to Expedite Commercialization of Sakigake Products: New Bureau Head
  October 28, 2015

• BUSINESS Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
  October 28, 2015

• REGULATORY 6 Drugs Get Sakigake Designation for Fast-Track Review
  October 27, 2015

• BUSINESS Jardiance Cardiovascular Data Boon for Japan’s Floundering SGLT-2 Inhibitor Space?
  October 26, 2015

• REGULATORY MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
  October 26, 2015

• BUSINESS Sandoz Looking to Emerge as Top Foreign Generic Maker in Japan in 5 Years
  October 23, 2015

• BUSINESS Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
  October 23, 2015

• REGULATORY New MHLW Economic Affairs Chief Visits Logistics Center, Says Distribution Key to Brightening Pharma Sector
  October 22, 2015

• BUSINESS Development of Osteoporosis Drugs in Homestretch, Odanacatib’s US Filing Expected by Year-End
  October 21, 2015

• BUSINESS Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
  October 21, 2015

ページ

• « 先頭
• ‹ Prev
• …
• 174
• 175
• 176
• 177
• 178
• 179
• 180
• 181
• 182
• …
• Next ›
• 最終 »